Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study

被引：0

作者：

Chibaudel, B.

Tournigand, C.

Mabro, M.

Bennamoun, M.

Artru, P.

Nguyen, S.

Bachet, J.

Aissat, N.

Blons, H.

Laurent-Puig, P.

De Gramont, A.

Andre, T.

机构：

[1] Hop St Antoine, F-75571 Paris, France

[2] Hop Foch, Suresnes, France

[3] Inst Mutualiste Montsouris, Paris, France

[4] Hop Prive Jean Mermoz, Lyon, France

[5] Ctr Hosp Beauvais, Beauvais, France

[6] Grp Hosp Pitie Salpetriere, F-75634 Paris, France

[7] GERCOR, Paris, France

[8] Hop Europeen Georges Pompidou, Paris, France

[9] Hop Europeen Georges Pompidou, APHP, Paris, France

[10] Hop La Pitie Salpetriere, Paris, France

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.3573

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3573

引用

页数：1